Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors MOST POPULAR COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms November 15, 2022 Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally... September 5, 2022 Five Questions With…Jae. May 19, 2022 Cancer waiting times: Latest updates and analysis May 11, 2023 Load more HOT NEWS How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy FLT3 Internal Tandem Duplication Measurable Residual Disease in Complete Remission Identifies... Why haven’t we cured cancer? – That Cancer Conversation This Harmful Chemical Is Still Being Used In Popular Household Products
